Current diagnosis of neurodegenerative diseases such as Parkinson’s disease (PD) is largely based on subjective assessments of motor symptoms observed later in the disease course. Furthermore, there is a lack of tools to accurately and quickly identify and monitor patients and track disease progression. Our novel, hand-held medical device enables the assessment of Parkinson’s disease in just three seconds. We non-invasively measure Ocular Microtremor (OMT), an intrinsic neurophysiological biomarker of brainstem function that exhibits a specific signature in PD. In addition, OMT has been validated as a biomarker for MS and stroke in over 15 publications. We are continuing validation of our device at Northumbria University, with the National Health Service (UK), and with a multi-national medical device company. Our device offers a fast, objective endpoint to affordably and frequently gather high-quality, enriched patient data to support better, more accurate decision-making in PD.
David van Zuydam, CEO - email@example.com
Mindaugus Norkus, PhD, CTO